Douglas Bell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Douglas Bell has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
Nelson Alphonso
Queensland Paediatric Cardiac Services, Queensland Children's Hospital, Brisbane, Australia; Faculty of Medicine, University of Queensland, Brisbane, Australia
6 shared publicationsPrem Venugopal
Queensland Pediatric Cardiac Research, Queensland Children's Hospital, Brisbane, Australia
6 shared publications- Kim Steven Betts
School of Population Health, Curtin University Perth Western Australia Australia
5 shared publications - Nelson Alphonso
Queensland Children's Hospital, Brisbane, Australia; School of Clinical Medicine, Children's Health Queensland Clinical Unit, University of Queensland, Brisbane, Australia; Child Health Research Centre, University of Queensland, Brisbane, Australia
5 shared publications Robert Justo
University of Queensland School of Medicine, University of Queensland, Brisbane, Australia; Queensland Pediatric Cardiac Research, Queensland Children's Hospital, Brisbane, Australia
4 shared publicationsHomayoun Jalali
University of Queensland School of Medicine, Brisbane, Australia
3 shared publications
Latest Publications
- 1 October 2021
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 11 (4)
Reactive Arthritis from Influenza Vaccination: A Novel Presentation That Mimics Prosthetic Joint Infection
Case: A 50-year-old woman with a history of bilateral knee replacements developed acute-onset bilateral painful knee effusions and inability to weight-bear. She was systemically well, but 2 days before the onset of her symptoms, she received an influenza vaccination. Synovial fluid analysis revealed white cell count (WCC) 190,000 × 109, 85% polymorphomuclear lymphocytes (PMN) on the left knee and WCC 252,200 × 109, 89% PMN on the right knee. Debridement and implant retention and polyethylene exchange was performed. Extended bacterial culture was negative as was 16s RNA polymerase chain reaction for remnants of bacterial DNA. No crystals were seen on any specimen. Both knees are stable and pain free at 12-month follow-up. Conclusion: Reactive arthritis secondary to influenza vaccination is a rare condition that can mimic prosthetic joint infection.
- 1 October 2021
- Published by Wolters Kluwer Health in JBJS Case Connector
- Vol. 11 (4)
Reactive Arthritis from Influenza Vaccination: A Novel Presentation That Mimics Prosthetic Joint Infection
Case: A 50-year-old woman with a history of bilateral knee replacements developed acute-onset bilateral painful knee effusions and inability to weight-bear. She was systemically well, but 2 days before the onset of her symptoms, she received an influenza vaccination. Synovial fluid analysis revealed white cell count (WCC) 190,000 × 109, 85% polymorphomuclear lymphocytes (PMN) on the left knee and WCC 252,200 × 109, 89% PMN on the right knee. Debridement and implant retention and polyethylene exchange was performed. Extended bacterial culture was negative as was 16s RNA polymerase chain reaction for remnants of bacterial DNA. No crystals were seen on any specimen. Both knees are stable and pain free at 12-month follow-up. Conclusion: Reactive arthritis secondary to influenza vaccination is a rare condition that can mimic prosthetic joint infection.
- 1 January 2021
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 161 (1) , 230-240
Truncus arteriosus repair: A 40-year multicenter perspective
- 1 January 2021
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 161 (1) , 230-240
Truncus arteriosus repair: A 40-year multicenter perspective
- 1 July 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (1) , 191-199.e1
The influence of coronary artery anatomy on mortality after the arterial switch operation
- 1 July 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (1) , 191-199.e1
The influence of coronary artery anatomy on mortality after the arterial switch operation
- 1 March 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 159 (3) , 1014-1025.e8
Complete atrioventricular septal defect repair in Australia: Results over 25 years
- 1 March 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 159 (3) , 1014-1025.e8
Complete atrioventricular septal defect repair in Australia: Results over 25 years
- 1 December 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 108 (6) , 1883-1888
Multicenter Experience With 500 CardioCel Implants Used for the Repair of Congenital Heart Defects
- 1 December 2019
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 108 (6) , 1883-1888
Multicenter Experience With 500 CardioCel Implants Used for the Repair of Congenital Heart Defects
- 1 October 2019
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 158 (4) , 1158-1167.e1
Biventricular repair versus Fontan completion for patients with d- or l-transposition of the great arteries with ventricular septal defect and left ventricular outflow tract obstruction
- 1 October 2019
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 158 (4) , 1158-1167.e1
Biventricular repair versus Fontan completion for patients with d- or l-transposition of the great arteries with ventricular septal defect and left ventricular outflow tract obstruction
- 21 April 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (1) , 85-91
Propensity-matched comparison of the long-term outcome of the Nunn and two-patch techniques for the repair of complete atrioventricular septal defects
OBJECTIVES: To compare the long-term performance of the Nunn and 2-patch techniques for the repair of complete atrioventricular septal defects. METHODS: Between January 1995 and December 2015, a total of 188 patients (Nunn n = 41; 2-patch n = 147) were identified from hospital databases. Univariable Cox regression was performed to calculate the risk of reintervention in each group. Propensity score matching was used to balance the Nunn group and the 2-patch group. RESULTS: Baseline characteristics including age at surgery, weight, trisomy 21, other cardiac anomalies, previous operations and preoperative atrioventricular valve regurgitation did not differ between the 2 groups. Overall, there was no difference in mortality between the 2 groups (P = 0.43). Duration of cardiopulmonary bypass (CPB) and myocardial ischaemia time were 29 min (P < 0.001) and 28 min (P < 0.001) longer, respectively, in the 2-patch group. Median follow-up was 10.8 years (2–21 years). Unadjusted Cox regression did not reveal a significant difference in the risk of reoperation for either group 9 years after initial surgery [hazard ratio (HR) (Nunn) 0.512, 95% confidence interval 0.176–1.49; Nunn 89%; 2-patch 82%]. This finding was reiterated from Cox regression performed on the propensity-matched sample (31 pairs). The probability of freedom from moderate or worse left atrioventricular valve regurgitation or left ventricular outflow obstruction was similar in the 2 groups. CONCLUSIONS: The Nunn and 2-patch techniques are comparable in terms of the long-term mortality and probability of freedom from reoperation, moderate or severe left atrioventricular valve regurgitation and left ventricular outflow obstruction. However, the duration of CPB and myocardial ischaemia is longer in the 2-patch group.
- 21 April 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (1) , 85-91
Propensity-matched comparison of the long-term outcome of the Nunn and two-patch techniques for the repair of complete atrioventricular septal defects
OBJECTIVES: To compare the long-term performance of the Nunn and 2-patch techniques for the repair of complete atrioventricular septal defects. METHODS: Between January 1995 and December 2015, a total of 188 patients (Nunn n = 41; 2-patch n = 147) were identified from hospital databases. Univariable Cox regression was performed to calculate the risk of reintervention in each group. Propensity score matching was used to balance the Nunn group and the 2-patch group. RESULTS: Baseline characteristics including age at surgery, weight, trisomy 21, other cardiac anomalies, previous operations and preoperative atrioventricular valve regurgitation did not differ between the 2 groups. Overall, there was no difference in mortality between the 2 groups (P = 0.43). Duration of cardiopulmonary bypass (CPB) and myocardial ischaemia time were 29 min (P < 0.001) and 28 min (P < 0.001) longer, respectively, in the 2-patch group. Median follow-up was 10.8 years (2–21 years). Unadjusted Cox regression did not reveal a significant difference in the risk of reoperation for either group 9 years after initial surgery [hazard ratio (HR) (Nunn) 0.512, 95% confidence interval 0.176–1.49; Nunn 89%; 2-patch 82%]. This finding was reiterated from Cox regression performed on the propensity-matched sample (31 pairs). The probability of freedom from moderate or worse left atrioventricular valve regurgitation or left ventricular outflow obstruction was similar in the 2 groups. CONCLUSIONS: The Nunn and 2-patch techniques are comparable in terms of the long-term mortality and probability of freedom from reoperation, moderate or severe left atrioventricular valve regurgitation and left ventricular outflow obstruction. However, the duration of CPB and myocardial ischaemia is longer in the 2-patch group.
- 7 February 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 56 (2) , 377-384
Homografts versus stentless bioprosthetic valves in the pulmonary position: a multicentre propensity-matched comparison in patients younger than 20 years†
OBJECTIVES: The aim of this study was to compare the performance of pulmonary homografts with stentless bioprosthetic valves [Medtronic Freestyle™ (Medtronic, Minneapolis, MN, USA)] in the pulmonary position in patients with congenital heart disease (CHD) younger than 20 years. METHODS: Between January 2000 and December 2017, 215 patients were retrospectively identified from hospital databases in 3 congenital heart centres in Australia. Valve performance was evaluated using standard criteria. Propensity score matching was used to balance the 2 treatment groups. RESULTS: Freedom from reintervention for patients who received a pulmonary homograft (n = 163) was 96%, 88% and 81% at 5, 10 and 15 years and for patients who received a Freestyle™ valve (n = 52) was 98%, 89% and 31% at 5, 10 and 15 years, respectively. Freedom from structural valve degeneration for patients with a homograft was 92%, 87% and 77% at 5, 10 and 15 years and for patients with a Freestyle valve was 96%, 80% and 14% at 5, 10 and 15 years, respectively. In the first 10 years, there was no difference in outcomes [reintervention hazard ratios (HR) = 0.69, 95% confidence intervals (CI) (0.20–2.42), P = 0.56; structural valve degeneration HR = 0.92 (0.34–2.51), P = 0.87]. After 10 years, the recipients of the Freestyle valves were at higher risk of both outcomes [reintervention HR = 7.89; 95% CI (2.79–22.34), P < 0.001; structural valve degeneration HR = 7.41 (2.77–19.84), P < 0.001]. The findings were similar when analysed by implantation in the orthotopic position and in the propensity-matched groups. CONCLUSIONS: The Freestyle stentless bioprosthetic valve is a comparable alternative to cryopreserved pulmonary homografts up to 10 years after implantation when implanted in an orthotopic pulmonary position in patients younger than 20 years with CHD.
- 7 February 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 56 (2) , 377-384
Homografts versus stentless bioprosthetic valves in the pulmonary position: a multicentre propensity-matched comparison in patients younger than 20 years†
OBJECTIVES: The aim of this study was to compare the performance of pulmonary homografts with stentless bioprosthetic valves [Medtronic Freestyle™ (Medtronic, Minneapolis, MN, USA)] in the pulmonary position in patients with congenital heart disease (CHD) younger than 20 years. METHODS: Between January 2000 and December 2017, 215 patients were retrospectively identified from hospital databases in 3 congenital heart centres in Australia. Valve performance was evaluated using standard criteria. Propensity score matching was used to balance the 2 treatment groups. RESULTS: Freedom from reintervention for patients who received a pulmonary homograft (n = 163) was 96%, 88% and 81% at 5, 10 and 15 years and for patients who received a Freestyle™ valve (n = 52) was 98%, 89% and 31% at 5, 10 and 15 years, respectively. Freedom from structural valve degeneration for patients with a homograft was 92%, 87% and 77% at 5, 10 and 15 years and for patients with a Freestyle valve was 96%, 80% and 14% at 5, 10 and 15 years, respectively. In the first 10 years, there was no difference in outcomes [reintervention hazard ratios (HR) = 0.69, 95% confidence intervals (CI) (0.20–2.42), P = 0.56; structural valve degeneration HR = 0.92 (0.34–2.51), P = 0.87]. After 10 years, the recipients of the Freestyle valves were at higher risk of both outcomes [reintervention HR = 7.89; 95% CI (2.79–22.34), P < 0.001; structural valve degeneration HR = 7.41 (2.77–19.84), P < 0.001]. The findings were similar when analysed by implantation in the orthotopic position and in the propensity-matched groups. CONCLUSIONS: The Freestyle stentless bioprosthetic valve is a comparable alternative to cryopreserved pulmonary homografts up to 10 years after implantation when implanted in an orthotopic pulmonary position in patients younger than 20 years with CHD.
- 31 January 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 56 (2) , 369-376
Long-term outcomes of surgery for pulmonary artery sling in children†
OBJECTIVES: Pulmonary artery (PA) sling is a rare vascular anomaly often associated with congenital tracheal stenosis. We describe the long-term outcomes with repair of this condition. METHODS: A retrospective study was conducted at 2 institutions. From 1984 to 2018, 33 patients with PA sling underwent repair. RESULTS: The median age at the time of surgery was 5.9 months (quartile 1–3: 2.5–12 months). Concomitant tracheal surgery was required in 21 patients (64%) where slide tracheoplasty was used in 11 patients (52%). There were no early deaths in patients who did not require tracheal surgery (n = 12). Operative mortality was 22% (2 of 9 patients) between 1984 and 1993, 11% (1 of 9 patients) between 1994 and 2003 and 6.7% (1 of 15 patients) between 2004 and 2018. The 15-year probability of survival for patients who had PA sling repair alone was 100%, and for patients who required PA sling and tracheal repair was 76 ± 10% (95% confidence interval 51–89%) (P = 0.08). The mean follow-up for survivors was 14 ± 9.8 years (3 months–33 years). All survivors were in the New York Heart Association functional class I/II at the last follow-up. Spirometry performed at a median age of 10.4 years after PA sling and tracheal surgery demonstrated obstructive lung defects with median forced expiratory volume in 1 s of 1.0 l (48% predicted), forced vital capacity of 1.5 l (74% predicted) and forced expiratory volume in 1 s/forced vital capacity of 0.69 (78% predicted). CONCLUSIONS: Early mortality after PA sling repair is determined by the need for tracheal surgery. Though late survival was excellent, and the majority of survivors remained asymptomatic, long-term respiratory assessment and follow-up is warranted for these patients.
- 31 January 2019
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 56 (2) , 369-376
Long-term outcomes of surgery for pulmonary artery sling in children†
OBJECTIVES: Pulmonary artery (PA) sling is a rare vascular anomaly often associated with congenital tracheal stenosis. We describe the long-term outcomes with repair of this condition. METHODS: A retrospective study was conducted at 2 institutions. From 1984 to 2018, 33 patients with PA sling underwent repair. RESULTS: The median age at the time of surgery was 5.9 months (quartile 1–3: 2.5–12 months). Concomitant tracheal surgery was required in 21 patients (64%) where slide tracheoplasty was used in 11 patients (52%). There were no early deaths in patients who did not require tracheal surgery (n = 12). Operative mortality was 22% (2 of 9 patients) between 1984 and 1993, 11% (1 of 9 patients) between 1994 and 2003 and 6.7% (1 of 15 patients) between 2004 and 2018. The 15-year probability of survival for patients who had PA sling repair alone was 100%, and for patients who required PA sling and tracheal repair was 76 ± 10% (95% confidence interval 51–89%) (P = 0.08). The mean follow-up for survivors was 14 ± 9.8 years (3 months–33 years). All survivors were in the New York Heart Association functional class I/II at the last follow-up. Spirometry performed at a median age of 10.4 years after PA sling and tracheal surgery demonstrated obstructive lung defects with median forced expiratory volume in 1 s of 1.0 l (48% predicted), forced vital capacity of 1.5 l (74% predicted) and forced expiratory volume in 1 s/forced vital capacity of 0.69 (78% predicted). CONCLUSIONS: Early mortality after PA sling repair is determined by the need for tracheal surgery. Though late survival was excellent, and the majority of survivors remained asymptomatic, long-term respiratory assessment and follow-up is warranted for these patients.
- 7 August 2018
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 28 (2) , 284-290
Durability of tissue-engineered bovine pericardium (CardioCel®) for a minimum of 24 months when used for the repair of congenital heart defects
This study aims to assess the performance of tissue-engineered bovine pericardium (CardioCel®) at 24 months and beyond when used for the repair of congenital heart defects. Between October 2012 and November 2014, CardioCel was implanted in 135 patients (140 procedures and 195 implants). Applications included the closure of septal defects (98, 50.3%), repair of pulmonary arteries (63, 32.3%), intra-atrial/intraventricular baffles (10, 5.1%), repair of systemic arteries (15, 7.7%), valve repair (5, 2.6%), repair of systemic veins (3, 1.5%) and Fontan operation (1, 0.5%). There were 19 (13.6%) procedures performed in neonates, 77 (55%) in infants and 44 (31.4%) in children older than 365 days. Eight patients (n = 135, 5.9%) required reintervention in 12 instances (n = 195, 6.2%, 6 catheters and 6 surgical). There was no echocardiographic or radiological evidence of calcification in any patient. Ten of the reinterventions (83%) occurred within the first 12 months. All the reinterventions occurred within 36 months. Freedom from reintervention at both 12 and 24 months was 95% [confidence interval (CI) 91-97] and at 36 months was 94% (CI 89-97). There was no statistical difference in freedom from reintervention when stratified by age or patch position. At 24 months and beyond the follow-up, the performance of CardioCel remains acceptable with good haemodynamic performance. There was no echocardiographic or radiological evidence of calcification in any patient. CardioCel performs comparably in systemic and pulmonary circulations.
- 7 August 2018
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 28 (2) , 284-290
Durability of tissue-engineered bovine pericardium (CardioCel®) for a minimum of 24 months when used for the repair of congenital heart defects
This study aims to assess the performance of tissue-engineered bovine pericardium (CardioCel®) at 24 months and beyond when used for the repair of congenital heart defects. Between October 2012 and November 2014, CardioCel was implanted in 135 patients (140 procedures and 195 implants). Applications included the closure of septal defects (98, 50.3%), repair of pulmonary arteries (63, 32.3%), intra-atrial/intraventricular baffles (10, 5.1%), repair of systemic arteries (15, 7.7%), valve repair (5, 2.6%), repair of systemic veins (3, 1.5%) and Fontan operation (1, 0.5%). There were 19 (13.6%) procedures performed in neonates, 77 (55%) in infants and 44 (31.4%) in children older than 365 days. Eight patients (n = 135, 5.9%) required reintervention in 12 instances (n = 195, 6.2%, 6 catheters and 6 surgical). There was no echocardiographic or radiological evidence of calcification in any patient. Ten of the reinterventions (83%) occurred within the first 12 months. All the reinterventions occurred within 36 months. Freedom from reintervention at both 12 and 24 months was 95% [confidence interval (CI) 91-97] and at 36 months was 94% (CI 89-97). There was no statistical difference in freedom from reintervention when stratified by age or patch position. At 24 months and beyond the follow-up, the performance of CardioCel remains acceptable with good haemodynamic performance. There was no echocardiographic or radiological evidence of calcification in any patient. CardioCel performs comparably in systemic and pulmonary circulations.